



Improving Meta-Analysis based GWAS Through Data Quality Management

Raul Ruggia Professor InCo, Univ. de la República Uruguay Hugo Naya Head of BioInformatics Institut Pasteur Montevideo Uruguay

- GWAS and Meta Analysis
- The approach
- GWAS data quality model
- GWAS data quality management tools
- Conclusions
- Perspectives

GWAS and Meta-Analysis

- Genome Wide Association Studies
 - Objective: associate genotypes to phenotypes
 - Technology allow to genotype thousands of markers (SNPs)
 - Screening (genotyped) of case (ill) and control populations
 - Genotype markers associated with the disease
 - Typical sample sizes are 1000 cases and controls
- Meta Analysis
- Statistical approaches that address a set of related research hypotheses combining the results of several existing studies





Combining GWAS Studies for Meta-analysis

subset: GWAS with CAD data recorded



HYPERTENSION



DIABETES



ALCOHOL and DRUG **ABUSE**



Challenge: data from different GWAS possess different specifications and quality levels

Goals:

Research problems:

- -Enable to combine different studies
- -Apply Data Quality Management Tools
- -Provide a data quality assessment environment to "GWAS Meta-Analysts"

Approach: META-ANALYSIS

NEW GWAS STUDY

ex: Coronary **Artery Disease** (CAD)



CROHN'S DISEASE



General Problem:

Costs and complexity of traditional GWAS



- Evaluate GWAS satisfaction & select the best combination of GWASs.
- Support interactive analysis of multiple properties on multiple GWAS.
- Compute data quality of GWAS combination.





Meta-analysis: Advantages and Challenges

Advantages:

- Increases sampling size and statistical power
- Imputation of markers between different platforms (HapMap):
 - increase in markers density
- Reduce costs of new studies
- NEW!! Information could be reused to addresses different targets or diseases (depending on phenotype info available)

Challenges:

- Source heterogeneity
 - differences in terms referring to similar concepts
 - quality heterogeneity (genotype and phenotype)
- Addressing similarities and differences between studies -> canonical study
- Population structure (internal and combined)

GWAS Meta-analyst Perspective

- Given a new target (e.g., a disease to study):
 - How to find the best subset of studies to combine?
 - Balance between maximizing the size of combined data against quality of the result (from data heterogeneity)
 - Which are the main quality properties to look for in GWASs?
 - Which GWAS combines favorably with others?
 - How to address the quality of the resulting dataset?
- This requires:
 - Specify a Data Quality Framework for GWAS
 - Manage multidimensional quality information in a highly interactive manner

Approach of the Project

- Specify a GWAS Data Quality model:
 - Representing the meaningful data quality properties for Meta-Analysis-based GWAS
 - Implementable -> include data quality measurement methods
 - Top-down approach: from high level goals to low level methods
- Implement GWAS data quality management Tool
 - Enable interactive exploration on data quality of the GWASs
 - Evaluate data quality of the existing GWASs
 - Define user oriented quality properties and their computation methods

Genotype


Phenotype

Population

GWAS Data Quality Model

- High level quality goals:
 - G1: Combinability
 - How combinable a GWAS is
 - G2: Study data quality
 - Accuracy, Precision, Completeness, Specificity, etc.
 - G3: Reputation
 - Depending on cross-validations, study follow-up, history of studies
 - G4: Accessibility
 - Availability, performance, privacy and security regulations
 - G5: Statistical power
 - How the study enables better statistical reasoning

Structure of the quality model:



Combinability of Genotype Data

SNP based plaftform overlap

	Affymetrix 100K	Affymetrix 500K	Illumina 100K	Illumina 550K	Perlegen 600K
Affymetrix 100K	100,0	23,5	4,2	32,0	22,4
Affymetrix 500K	5,5	100,0	3,2	16,9	26,8
Illumina 100K	4,5	14,7	100,0	22,5	23,5
Illumina 550K	6,7	15,2	4,4	100,0	35,1
Perlegen 600K	4,3	22,4	4,3	32,6	100,00

COMMERCIAL GENOTYPING PLATFORMS








SNP set intersection based on refSNP numbers (rs) from dbSNP Project

Correlated SNPs groups

	SNP ₁	SNP ₂	3.74	SNP _n
Platform ₁	1	0.90		1
Platform _M	0.85	0.86		0.87




SNP coverage measure based on Linkage Disequilibrium (LD) [HapMap Proj.]

Max { r²(SNP_n, SNP(platform_M)) }

Phenotype: Mapping Terms to SNOMED


Research




CliniClue®


SNOMED

browser





Quality Model -> Management Tool




Identify GWASs with adequate quality level in the variables of interest.

GWAS Data Quality Management tool

- Specify GWAS data quality properties
- Measure quality values on each GWAS
- 3. Analysis of quality requirement satisfaction on multiple GWAS
- 4. Analyze of quality results on GWAS combination

Adjust quality property definitions

Data Quality Management Tool



Defines GWAS-oriented high level properties, based on basic properties and metrics.

Computes quality properties on GWAS data. It is based on source GWAS data quality as well as on the data combination operations.

Interactive analysis of quality values. Based on the GWAS quality goals.

Research

Technical Approach

- Quality analysis -> OLAP + Customizations
 - Using SQL Server 2008 and Analysis Services
 - Specific Roll-Up functions. Intensive use of MDX language
 - DSLs: GWAS specific languages for quality properties and for analysis conditions
 - Starting with Excel as OLAP client, towards a specific interface
- Using SNOMED as medical ontology
 - The basis to define phenotypic quality properties
 - Assisted mapping tool: GWAS -> SNOMED
- Large data processing -> Cloud computing
 - Genomic data: aprox. 50 GB (hundreds of GB in public repos)

Conclusions



- Meta-analysis is a powerful tool for performing GWAS
 - However, studies' combinability should be guided in a clear/objective way
 - The developed Data Quality Framework for GWAS enable to systematically apply such approach
- Specification of GWAS Data Quality Framework:
 - Constitutes a main achievement of the project; however, still remains much to be done
 - Privacy regulations and information restrictions are main issues for info availability
- The implemented tool:
 - Provides analytical functions to explore the data quality characteristics of GWAS
 - Intends to guide the analyst in the process of reusing studies
- The prototype is based on several available tools:
 - Shows the potential of "general purpose" software to be used in the scientific area

Perspectives



GWAS:

- Extending quality goals and metrics (on genotype and phenotype info)
- Specifying "population environment" quality goals and metrics
- Developing a module for automatic search of risk factors
- Addressing privacy and data restrictions through a GWAS Data Quality Service?

Biological data quality:

- Massive methods (High Throughput) are nowadays pervasive in biology and data quality approaches could led light in data sharing
- Extending our approach to microarrays or Next Generation Sequencing is straightforward

Medical/Healthcare application:

- The concepts and quality metrics developed could be interesting in Medical/Healthcare recording
- Assisted Medical Diagnosis is another very interesting application



Thank you very much

- Contact:
 - http://www.fing.edu.uy/inco/grupos/sibio/gwas/
 - Hugo Naya, naya@pasteur.edu.uy
 - Raul Ruggia, <u>ruggia@fing.edu.uy</u>

Research

Microsoft®

Your potential. Our passion.™

© 2009 Microsoft Corporation. All rights reserved. Microsoft, Windows Vista and other product names are or may be registered trademarks and/or trademarks in the U.S. and/or other countries. The information herein is for informational purposes only and represents the current view of Microsoft Corporation as of the date of this presentation. Because Microsoft must respond to changing market conditions, it should not be interpreted to be a commitment on the part of Microsoft, and Microsoft cannot guarantee the accuracy of any information provided after the date of this presentation. MICROSOFT MAKES NO WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, AS TO THE INFORMATION IN THIS PRESENTATION.